• Valion Bio posted a net loss of USD 6.2 million for quarter ended March 31, 2026, widening from a net loss of USD 1.5 million a year earlier.
• Operating loss widened to USD 5.63 million as total operating expenses climbed to USD 5.63 million, led by research and development expense of USD 1.85 million and selling, general and administrative costs of USD 3.78 million.
• Cash and cash equivalents were USD 7.2 million at March 31, 2026, with cash used in operating activities of USD 5.01 million during the quarter.
• Company flagged substantial doubt about its ability to continue as a going concern within one year, citing cash levels and burn rate.
• Michael K. Handley was appointed CEO in March; Valion also reported a 200-fold manufacturing scale-up for Entolimod at 50-liter fermentation volume and validated inventory materials tied to a USD 750,000 license milestone liability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-017142), on May 14, 2026, and is solely responsible for the information contained therein.